EGFR and lung carcinoma: EGFR activation, induced by mutations, has been observed to induce upregulation of glutamine metabolism in some cancer studies.[4, 26] A strategy to inhibit GLS 1 in addition to EGFR block has shown promising anti‐tumor effects in preclinical colon and lung cancer models.[4, 27] Therefore, we hypothesized that tumors with glutamine addiction, might benefit from preferential glutamine inhibition in the TME, and thereby, enhance the efficacy of EVax against EGFR‐driven lung tumorigenesis.